Skip to content

Clinical study of human amniotic epithelial cell transplantation for treatment of premature ovarian failure

Clinical study of human amniotic epithelial cell transplantation for treatment of premature ovarian failure

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033530
Enrollment
Unknown
Registered
2020-06-04
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ovarian insufficiency

Interventions

experimental group:Arterial infusion of human amniotic epithelial cells

Sponsors

International Peace Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Subjects who met the diagnostic criteria of POI: aged 40 IU / L (repeat twice every 4 weeks). 2. Patients who are diagnosed as infertile and require fertility; 3. Blood ß - hCG negative subjects; 4. Subjects who have not received other clinical trials within 3 months before the clinical study; 5. The patient agreed to participate in the study and signed the informed consent before participating in any research related activities.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumor history in the past 5 years; 2. Patients with severe functional damage of important organs; 3. The object of abnormal karyotype; 4. Patients with abnormal coagulation mechanism; 5. Patients with severe pelvic adhesion; 6. Patients whose acute and chronic inflammation of gynecology has not been controlled; 7. Patients with congenital adrenal hyperplasia; 8. Patients with Cushing's syndrome; 9. Patients with thyroid dysfunction; 10. Patients with hyperprolactinemia; 11. Patients with pituitary amenorrhea or hypothalamic amenorrhea; 12. Patients with thrombophlebitis, including venous thrombosis and arterial thrombosis; 13. Patients with ovarian cyst or ovarian surgery; 14. Objects with high tumor markers; 15. Pregnancy or lactation; 16. Patients receiving other treatments that may affect the efficacy and safety of stem cells; 17. Patients with severe drug allergy; 18. Patients with abnormal blood routine, coagulation time, liver and kidney function, ECG, chest film, hepatitis B and hepatitis C virus index, HIV, TPAB and other abnormalities were examined one month before operation. 19. Patients with abnormal mental diseases; 20. The patient participates in any other clinical study using intervention drugs or examination procedures at the same time; 21. Patients considered unsuitable by the researchers.

Design outcomes

Primary

MeasureTime frame
Liver function routine;kidney function;Electrolyte;blood test routine;Full set of sex hormones;Gynecological examination;Gynecology three-dimensional ultrasound;

Countries

China

Contacts

Public ContactDongmei Lai

International Peace Maternity and Child Health Hospital

laidongmei@hotmail.com+86 18017316060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026